Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $40.8 million.

  • Intellia Therapeutics' Accumulated Expenses fell 2024.18% to $40.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year decrease of 2024.18%. This contributed to the annual value of $55.4 million for FY2024, which is 1740.16% down from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Accumulated Expenses is $40.8 million, which was down 2024.18% from $41.6 million recorded in Q2 2025.
  • Intellia Therapeutics' Accumulated Expenses' 5-year high stood at $67.0 million during Q4 2023, with a 5-year trough of $21.2 million in Q1 2021.
  • Over the past 5 years, Intellia Therapeutics' median Accumulated Expenses value was $44.8 million (recorded in 2023), while the average stood at $45.8 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 14164.17% in 2021, then tumbled by 2024.18% in 2025.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Accumulated Expenses stood at $43.3 million in 2021, then surged by 40.56% to $60.9 million in 2022, then increased by 10.09% to $67.0 million in 2023, then fell by 17.4% to $55.4 million in 2024, then decreased by 26.22% to $40.8 million in 2025.
  • Its Accumulated Expenses was $40.8 million in Q3 2025, compared to $41.6 million in Q2 2025 and $40.8 million in Q1 2025.